Trial · NCT04558918
Adverse events172
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 172
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Breakthrough haemolysis | Blood and lymphatic system disorders | LNP023 200mg b.i.d. (Randomized Treatment Period) | 2 | 62 | |
| other | Breakthrough haemolysis | Blood and lymphatic system disorders | Anti-C5 Antibody (Randomized Treatment Period) | 6 | 35 | |
| other | Breakthrough haemolysis | Blood and lymphatic system disorders | LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 6 | 62 | |
| other | Breakthrough haemolysis | Blood and lymphatic system disorders | Any LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 7 | 96 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | LNP023 200mg b.i.d. (Randomized Treatment Period) | 3 | 62 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Anti-C5 Antibody (Randomized Treatment Period) | 0 | 35 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 3 | 62 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Any LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 5 | 96 | |
| other | Abdominal pain | Gastrointestinal disorders | LNP023 200mg b.i.d. (Randomized Treatment Period) | 4 | 62 | |
| other | Abdominal pain | Gastrointestinal disorders | Anti-C5 Antibody (Randomized Treatment Period) | 1 | 35 | |
| other | Abdominal pain | Gastrointestinal disorders | LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 5 | 62 | |
| other | Abdominal pain | Gastrointestinal disorders | Any LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 5 | 96 | |
| other | Diarrhoea | Gastrointestinal disorders | LNP023 200mg b.i.d. (Randomized Treatment Period) | 9 | 62 | |
| other | Diarrhoea | Gastrointestinal disorders | Anti-C5 Antibody (Randomized Treatment Period) | 2 | 35 | |
| other | Diarrhoea | Gastrointestinal disorders | LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 10 | 62 | |
| other | Diarrhoea | Gastrointestinal disorders | Any LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 12 | 96 | |
| other | Nausea | Gastrointestinal disorders | LNP023 200mg b.i.d. (Randomized Treatment Period) | 6 | 62 | |
| other | Nausea | Gastrointestinal disorders | Anti-C5 Antibody (Randomized Treatment Period) | 1 | 35 | |
| other | Nausea | Gastrointestinal disorders | LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 8 | 62 | |
| other | Nausea | Gastrointestinal disorders | Any LNP023 200mg b.i.d. (Randomized Treatment Period + Extension Treatment Period) | 11 | 96 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04558918/events